ShiSi Pharmaceutical Group: Obtained drug production registration approval for Calcium Gluconate Sodium Chloride Injection and Metronidazole Sodium Chloride Injection.

Sishi Pharmaceutical Group announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for Glucose Calcium Chloride Sodium Injection, which belongs to the third category of chemical drugs and is considered to have passed consistency evaluation. Glucose Calcium Chloride Sodium Injection is mainly used to treat acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Together with the Glucose Calcium Chloride Sodium Injection approved on June 4, 2025, and the Glucose Calcium Injection approved on July 18, 2025, the group has established a series of calcium preparation products.